

**COMMUNITY CARE AND MANAGEMENT OF
LONGER-TERM CONDITIONS - ASSESSMENT 1**

Osteoarthritis Booklet

Programme: MSc Public Health and Social Care in Practice

Module name: Community care and Management of longer-term conditions

Module code: LCHS7003

Student name: MISHA GIRISHBHAI PATEL

Student ID: 2540912

Lecturer: MUHAMMED KHAN

TABLE OF CONTENTS

SECTION 1: Explanation, Evaluation, and Epidemiology of Osteoarthritis

- **1.1 Clinical Definition and Pathophysiology**
 - Molecular Pathophysiology of Cartilage Degradation
 - Subchondral Bone Remodeling Cascades
- **1.2 Global and United Kingdom Epidemiology**
 - Global Prevalence Trends and Gender Disparities
 - United Kingdom Burden and Regional Disparities
 - Demographic Megatrends: Population Aging & Rising BMI
- **1.3 Multifactorial Aetiology and Risk Factors**
 - Systemic Predisposing Factors (Cellular Senescence, Hormonal Changes, Genetics)
 - Localized Biomechanical Factors (Obesity, Macro-Trauma, Occupational Overload)

SECTION 2: Critical Evaluation of Impact and Evidence-Based Treatments

- **2.1 Multidimensional Impact Analysis**
 - Physical Implications: Atrophy, Deconditioning & Falls Risk
 - Psychological Implications: Central Sensitization & Distress
 - Social & Familial Implications: Vocation Loss & Caregiver Burden
- **2.2 Evidence-Based Treatments via the NHS UK**
 - Tier 1: Core Non-Pharmacological Interventions (Exercise & Weight Management)

- Tier 2: Pharmacological Adjuncts (Topical/Oral NSAIDs & Localized Injections)
- Tier 3: Surgical Interventions (Total Joint Reconstruction & Arthroplasty)

SECTION 3: Theoretical Perspectives, Models, and Policy Frameworks

- **3.1 Comparative Theoretical Models for Improved Outcomes**
 - The UK Model: The House of Care Framework
 - The International Model: WHO Innovative Care for Chronic Conditions (ICCC)
 - Comparative Framework Analysis
- **3.2 Critical Examination of Political Health and Social Care Agendas**
 - The NHS Long Term Plan & First Contact Practitioners (FCPs)
 - The Major Conditions Strategy & Digital Health Horizons
 - Integrated Care Systems (ICSs) & Cross-Sector Integration

SECTION 4: Recommendations for Person-Centred Care and Strategic Improvement


- **Recommendation 1:** Standardize Multi-Disciplinary Social Prescribing Pathways
- **Recommendation 2:** Implement Universal Co-Produced Personalised Care and Support Plans (PCSPs)
- **Recommendation 3:** Expand Hybrid Digital Self-Management Support Programs
- **Recommendation 4:** Embed Proactive Advance Care Planning into Multi-Morbid End-of-Life Frameworks

REFERENCES

SECTION 1: Explanation, Evaluation, and Epidemiology of Osteoarthritis

1.1 Clinical Definition and Pathophysiology

Osteoarthritis (OA) is a chronic, degenerative, non-communicable musculoskeletal disorder. It is characterized by the progressive cellular and mechanical breakdown of articular cartilage, subchondral bone remodeling, osteophyte (bone spur) formation, and low-grade secondary synovitis (joint lining inflammation) (Hunter and Bierma-Zeinstra, 2019). Historically, OA was mischaracterized as a passive, inevitable "wear-and-tear" phenomenon associated with chronological aging. However, contemporary molecular science redefines OA as an active, aberrant biochemical process. This process involves systemic and localized metabolic dysfunction, cellular senescence, and an inflammatory cascade that affects the entire joint as an organ (Kraus et al., 2015; Loeser et al., 2012).



The pathophysiology of OA centers on a fundamental imbalance between extracellular matrix (ECM) synthesis and degradation within the articular cartilage. Chondrocytes—the sole specialized cell type residing in cartilage—respond to chronic mechanical stress, repetitive loading, and metabolic insults by shifting from an anabolic (reparative) state to a highly catabolic (destructive) phenotype (Loeser et al., 2012). These dysfunctional chondrocytes upregulate the secretion of pro-inflammatory cytokines, most notably Interleukin-1 Beta (IL-1 β) and Tumor Necrosis Factor-Alpha (TNF- α) (Kapoor et al., 2011).

These inflammatory signaling pathways trigger an intracellular cascade that stimulates the production of major proteolytic enzymes:

- **Matrix Metalloproteinases (MMPs):** Particularly MMP-1, MMP-3, and MMP-13, which target and degrade the dense Type II collagen network that provides cartilage with its tensile strength (Martel-Pelletier et al., 2016).
- **Aggrecanases:** Specifically A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS-4 and ADAMTS-5), which enzymatically cleave proteoglycans (aggrecan molecules), stripping the cartilage of its osmotic properties and shock-absorbing capacity (Martel-Pelletier et al., 2016).

Flowchart Stage	Biochemical / Physiological Process	Molecular Key Players & Signals	Pathological Action & Matrix Impact	Core Academic Reference(s)
1. Mechanical Stress & Metabolic Insult	Initial joint overload and systemic metabolic irritation.	* Excess vertical shear stresses. * Systemic adipokines (leptin, adiponectin).	Disrupts the resting homeostatic microenvironment of the articular cartilage, triggering intracellular stress signaling in resident cells.	Felson (2013); Berenbaum et al. (2013)
2. Chondrocyte Phenotypic Shift	Transition of cartilage cells from an anabolic to a highly catabolic state.	* Altered mechanoreceptor signaling (integrins). * Transcripts favoring tissue destruction.	Chondrocytes permanently cease production of healthy type II collagen and proteoglycans, switching instead to active matrix destruction.	Loeser et al. (2012)

3. Cytokine Upregulation	Autocrine and paracrine amplification of the local joint inflammatory cascade.	* Interleukin-1 Beta (IL-1β). * Tumor Necrosis Factor-Alpha (TNF-α).	These primary cytokines bind to chondrocyte surface receptors, triggering downstream pathways (like NF- κ B) that initiate heavy enzyme production.	Kapoor et al. (2011)
4. Enzyme Release	Secretion of specialized, destructive proteolytic enzymes into the extracellular matrix (ECM).	* Matrix Metalloproteinases (MMP-1, MMP-3, MMP-13). * Aggrecanases (ADAMTS-4, ADAMTS-5).	Released directly into the local cartilage matrix, preparing to enzymatically cleave the structural pillars of the joint tissue.	

As the cartilage thins, develops fissures, and erodes, the protective joint space narrows. This transfers excessive biomechanical loading directly to the subchondral bone. In response to this abnormal mechanical stress, the subchondral bone undergoes dramatic structural remodeling:

- **Eburnation:** Bony hardening and polishing due to direct bone-on-bone friction.
- **Subchondral Cysts:** Micro-fractures allow synovial fluid to penetrate the bone, forming fluid-filled cystic lesions (Loeser et al., 2012).
- **Osteophytosis:** New bone formation (osteophytes) at the joint margins, driven by abnormal signaling of transforming growth factors, in a pathological attempt to stabilize the joint (Hunter and Bierma-Zeinstra, 2019).

Concurrently, cartilage degradation products shed into the joint cavity, triggering a secondary, low-grade inflammatory response within the surrounding synovium (synovitis). This leads to synovial thickening,

localized edema, and increased production of low-viscosity synovial fluid, which clinically manifests as joint swelling, warmth, and persistent pain (Kapoor et al., 2011).

1.2 Global and United Kingdom Epidemiology

The epidemiological burden of OA is accelerating globally, driven by two key megatrends: population aging and rising body mass index (BMI) cohorts (Thomas et al., 2014).

Megatrend	Pathological & Epidemiological Mechanism	Impact on Global Burden (Epidemiology & YLDs)	Impact on United Kingdom Burden (NHS & Society)	Core Academic Reference(s)
Population Aging (Increasing Life Expectancy)	*Chronological aging leads to cellular senescence in chondrocytes. *Senescent cells express the Senescence-Associated Secretory Phenotype (SASP), secreting pro-inflammatory cytokines and matrix-degrading enzymes while ignoring anabolic repair cues.	* Contributes to over 595 million cases worldwide (prevalence of ~8.13%). * Positions OA as the 15th leading cause of Years Lived with Disability (YLDs) globally as lifespans extend.	* 18.2% of UK adults aged 45+ live with knee OA; 10.9% live with hip OA. * Drives over 6.5 million GP consultations annually, overwhelming baseline primary care systems.	Loeser (2010); Steinmetz et al. (2023); Versus Arthritis (2024)
Rising Body Mass Index (BMI) (Obesity Trends)	*Mechanical: Compressive vertical loading forces across articular surfaces are multiplied during walking. * Metabolic: White adipose tissue secretes systemic adipokines (leptin,	*Accelerates knee OA rates globally (now at 5.01% overall). * Explains rising rates of bilateral hand OA in obese	*Knee OA is heavily concentrated in England (exceeding 4.5 million cases), closely mirroring national obesity mapping.	Messier et al. (2013); Berenbaum et al. (2013); Versus Arthritis (2024)

	resistin) that trigger low-grade inflammatory cascades in non-weight-bearing joints.	cohorts due to systemic biochemical cartilage degradation.	*Promotes regional health inequalities, with fast-growing prevalence in deprived UK areas.	
--	--	--	--	--

Global Epidemiology

According to data from the Global Burden of Disease (GBD) Study, the global prevalence of OA stands at approximately 8.13%, equating to over 595 million people worldwide (Steinmetz et al., 2023). OA is a leading driver of physical restriction and functional limitation, ranking as the 15th highest cause of Years Lived with Disability (YLDs) globally (Cross et al., 2014).

The anatomical distribution of the disease is highly skewed:

- **Knee OA** accounts for approximately 5.01% of the global burden.
- **Hand OA** accounts for approximately 2.61%.
- **Hip OA** accounts for approximately 0.48% (Steinmetz et al., 2023).

Marked gender disparities exist globally. The age-standardized prevalence rate for females is approximately 9.80%, compared to 6.44% for males (Cui et al., 2020). This disparity is largely attributed to post-menopausal biological shifts and gender-specific differences in joint anatomy and biomechanics (Mahjan et al., 2011).

United Kingdom Epidemiology

In the UK, data synthesized by Versus Arthritis demonstrates that OA is the country's leading cause of chronic pain and physical disability (Versus Arthritis, 2024). Approximately 8.5 million individuals in the UK live with clinically diagnosed OA (Versus Arthritis, 2022).

The table below outlines key epidemiological metrics for OA in the United Kingdom:

Anatomical Site / Impact Metric	Demographic Group	UK Prevalence / Metric Value	Key Contextual Details
---------------------------------	-------------------	------------------------------	------------------------

Knee Osteoarthritis	Adults aged 45+	18.2% (approx. 1 in 5 adults)	England alone accounts for over 4.5 million cases; heavily linked to localized obesity trends (Versus Arthritis, 2024).
Hip Osteoarthritis	Adults aged 45+	10.9% (approx. 1 in 9 adults)	Leads to profound mobility restrictions and represents the majority of total joint replacement procedures (Versus Arthritis, 2024).
Workforce Retention	Employed OA Patients	61% expect to or have retired early	Reflects the severe socioeconomic impact and loss of economic productivity due to chronic pain (MacDonald et al., 2014).
Primary Care Workload	General Population	6.5 million consultations annually	Imposes a significant operational and financial burden on NHS general practice services (Versus Arthritis, 2022).

Regional disparities across the UK home nations reveal distinct geographical trends. Absolute numbers are highest in England, where knee OA exceeds 4.5 million cases (Versus Arthritis, 2024). However, Northern Ireland has demonstrated the fastest relative increase in prevalence over the last three decades, rising by more than 76% (MacDonald et al., 2014; Versus Arthritis, 2024). This steep upward trajectory is closely tied to rising regional obesity rates and localized socioeconomic deprivation, highlighting the role of social determinants of health in chronic joint disease (Wilkie et al., 2014).

1.3 Multifactorial Aetiology and Risk Factors

The etiology of OA is highly complex and multifactorial. The condition rarely develops along a simple linear pathway; instead, it arises from a convergence of systemic predisposing traits and localized biomechanical stressors (Felson, 2013).

Risk Factor Category	Specific Etiological Driver	Underlying Biological or Mechanical Mechanism	Impact on the Joint as an Organ	Academic Reference
Systemic Predispositions	Advanced Age & Cellular Senescence	Chondrocytes enter a State of Senescence-Associated Secretory Phenotype (SASP)	Halts natural matrix synthesis; increases the secretion of destructive	Loeser (2010)

		with shortened telomeres.	proteases (MMPs).	
	Female Biological Sex & Menopause	Post-menopausal decline in systemic estrogen removes natural anti-inflammatory signaling from chondrocyte receptors ($ER\alpha$ / $ER\beta$).	Accelerates articular cartilage breakdown due to loss of hormonal joint protection.	Mahjan et al. (2011)
	Genetic Polymorphisms	Variations in key susceptibility loci, such as the growth differentiation factor 5 (GDF5) and COL11A1 genes.	Results in congenital vulnerabilities or structurally weaker collagen networks in the joint matrix.	Martel-Pelletier et al. (2016)
Localized Biomechanical Factors	Obesity & Adiposity	Direct increase in vertical contact loading across knees/hips combined with high systemic adipokine secretion (leptin, resistin).	Alters joint kinematics while fat-derived chemical markers trigger matrix degradation pathways.	Messier et al. (2013); Berenbaum et al. (2013); King et al. (2013)
	Macro-Trauma (e.g., ACL / Meniscal Tears)	Direct disruption to joint cartilage structures or soft tissue stabilizers during impact.	Alters contact mechanics and shifts focal shear stress onto previously healthy cartilage layers.	Øiestad et al. (2010)
	Occupational Overload	Prolonged, repetitive knee bending, heavy lifting, or vibration-induced cyclic	Creates minor micro-fractures in subchondral bone structures faster	Felson (2013); Loeser et al. (2012)

		stress on specific joints.	than the body can repair them.	
--	--	----------------------------	--------------------------------	--

Systemic Predisposing Factors

- **Advanced Age and Cellular Senescence:** Aging is the strongest risk factor for OA. With advancing age, chondrocytes undergo telomere shortening and enter a State of Senescence-Associated Secretory Phenotype (SASP) (Loeser, 2010). These senescent cells secrete high levels of pro-inflammatory cytokines and matrix-degrading enzymes while becoming increasingly unresponsive to anabolic growth factors, such as Transforming Growth Factor-Beta (TGF- β), halting natural cartilage repair (Loeser, 2010).
- **Biological Sex and Hormonal Dynamics:** The incidence of OA increases sharply in women post-menopause. This trend suggests that the decline in systemic estrogen levels plays a key role in joint vulnerability (Mahjan et al., 2011). Chondrocytes express functional estrogen receptors (ER α and ER β) that normally exert a protective, anti-inflammatory effect on cartilage. The loss of estrogen post-menopause removes this barrier, accelerating cartilage degradation (Mahjan et al., 2011).
- **Genetic Polymorphisms:** Genome-wide association studies have identified several genetic susceptibility loci for OA. Key among these are polymorphisms in the Growth Differentiation Factor 5 (GDF5) gene, which is critical for joint development, and the COL11A1 gene, which regulates the assembly of type II collagen fibrils (Martel-Pelletier et al., 2016). These genetic variations can result in structurally weaker cartilage that is more susceptible to normal mechanical wear.

Localized Biomechanical Factors

- **Obesity and Metabolic Loading:** Obesity is a major, modifiable risk factor that influences OA through both mechanical and biochemical pathways. Mechanically, excess body weight increases the vertical loading force across weight-bearing joints (primarily the knees and hips) during movement (Messier et al., 2013). Biochemically, white adipose tissue acts as an active endocrine organ, secreting pro-inflammatory cytokines and adipokines, including leptin, adiponectin, and resistin (Berenbaum et al., 2013). These systemic molecules circulate to the joint tissues, where they stimulate chondrocytes to release matrix metalloproteinases, accelerating cartilage loss even in non-weight-bearing joints like the hands (Berenbaum et al., 2013; King et al., 2013).

- **Joint Injury and Structural Aberration:** Macro-trauma to joint structures—such as anterior cruciate ligament (ACL) tears, meniscal damage, or intra-articular fractures—is a primary trigger for post-traumatic osteoarthritis (PTOA) (Øiestad et al., 2010). These injuries cause immediate focal damage to the articular cartilage and permanently alter the joint's contact mechanics. This leads to chronic, localized shear stress on the remaining healthy cartilage, accelerating its wear over time (Øiestad et al., 2010).

SECTION 2: Critical Evaluation of Impact and Evidence-Based Treatments

2.1 Multidimensional Impact Analysis

Osteoarthritis has a profound impact across an individual's entire biopsychosocial ecosystem, cascading from localized joint dysfunction to widespread personal and societal disruptions (Bedson et al., 2016).

Impact Dimension	Specific Clinical Feature / Outcome	Underlying Pathological or Psychosocial Mechanism	Consequent Healthcare & Lifestyle Burden	Academic Reference
Physical	Mechanical Pain & Stiffness	Progressive thinning and breakdown of articular cartilage, leading to bone-on-bone friction and secondary low-grade synovitis. Short-duration stiffness resolves within 30 minutes.	Restricts activities of daily living (ADLs); drives individuals toward a sedentary lifestyle to avoid discomfort.	NICE (2022); Kapoor et al. (2011)
	Muscle Atrophy & Falls Risk	Pain-avoidant adaptations trigger arthrogenic muscle inhibition, leading to localized wasting (e.g., quadriceps muscle thinning) and dynamic joint instability.	Triples the objective risk of falls in older patient cohorts; impairs independent mobility and balance.	Hurley et al. (2012); Stubbs et al. (2016)
	Cardiovascular Deconditioning	Chronic physical inactivity driven by a	Elevates the patient's long-term risk of	Stubbs et al. (2016)

		fear of movement (kinesiophobia) initiates an overall physical deconditioning cascade.	developing severe secondary comorbidities like metabolic syndrome, Type 2 diabetes, and ischemic heart disease.	
Psychological	Central Sensitization	Persistent, unmanaged nociceptive signaling from the joint alters central nervous system processing, causing the spinal cord and brain to amplify pain perceptions.	Clinically manifests as hyperalgesia and allodynia, making ordinary movements feel disproportionately painful.	Neogi (2013)
	Anxiety & Depression	Chronic, unremitting joint pain and the loss of functional independence diminish subjective health status and emotional resilience.	Up to 40% of diagnosed OA cohorts experience major depressive or anxiety disorders, complicating standard treatment adherence.	Sharma et al. (2016)
	Sleep Fragmentation	Nocturnal joint aching and difficulty finding a comfortable resting position disrupt natural, restorative sleep architecture.	Accelerates daytime fatigue, decreases cognitive capacity, and fundamentally lowers the patient's threshold for pain tolerance.	Hawker et al. (2011)
Social / Familial	Social Withdrawal	Physical mobility limitations and widespread systemic exhaustion limit participation in recreational, civic, and social activities.	Drives profound feelings of loneliness, personal isolation, and progressive detachment from supporting community networks.	Wilkie et al. (2014)

	Loss of Vocation	Physical impairments prevent individuals from meeting the manual or positional demands of standard employment environments.	Approximately 61% of working OA patients face early retirement or long-term sick leave, causing personal financial strain and lost economic productivity.	Gignac et al. (2011); MacDonald et al. (2014)
	Caregiver Burden	Functional decline shifts the daily physical and operational responsibilities of independence onto immediate family members.	Relatives experience high levels of informal caregiver burden, characterized by emotional burnout, physical fatigue, and shifting family dynamics.	Carey et al. (2012); Morden et al. (2015)

Physical Implications

The primary clinical features of OA include mechanical pain that worsens with weight-bearing activities and improves with rest, short-duration morning stiffness (typically resolving within 30 minutes), joint crepitus (a grating or cracking sensation), bony enlargement, and a progressive loss of joint range of motion (NICE, 2022).

As articular cartilage erodes, patients often experience quadriceps muscle inhibition and subsequent atrophy. This occurs as a protective, pain-avoidant adaptation to joint discomfort, altering gait mechanics (Hurley et al., 2012). This muscle wasting impairs dynamic joint stability, triples the risk of falls in older cohorts, and initiates a "deconditioning cascade" (Stubbs et al., 2016). In this cycle, fear of pain leads to a sedentary lifestyle, which in turn increases the risk of serious secondary comorbidities, including cardiovascular disease, metabolic syndrome, and Type 2 diabetes (Stubbs et al., 2016).

Psychological Implications

The persistence of unmanaged nociceptive signals from a degenerating joint can alter central nervous system processing over time. This leads to central sensitization—a neurological state where the brain and spinal cord amplify pain signals, causing hyperalgesia (increased sensitivity to pain) and allodynia (pain from non-painful stimuli) (Neogi, 2013). This chronic pain loop is closely linked to psychological distress:

- **Mental Health:** Clinical audits show that up to 40% of individuals with OA experience significant anxiety or major depressive disorders (Sharma et al., 2016).

- **Cognitive Decline:** Chronic pain disrupts sleep patterns. This sleep fragmentation impairs cognitive function, reduces emotional resilience, and lowers self-efficacy, making the subjective experience of physical pain feel even more intense (Hawker et al., 2011).

Social and Familial Implications

Socially, OA restricts participation in recreational, social, and civic activities, often leading to isolation and loneliness (Wilkie et al., 2014). The financial impact of the disease can also be significant. Many individuals experience reduced earning capacity or are forced to retire early due to physical limitations (Gignac et al., 2011).

At the family level, the caregiving burden often falls on immediate relatives. Informal caregivers frequently experience high levels of caregiver burden, characterized by physical fatigue, emotional exhaustion, and financial strain (Carey et al., 2012). As an individual transitions from an independent family member to a care-dependent partner, family dynamics can shift, sometimes causing relational tension and stress within the household (Morden et al., 2015).

2.2 Evidence-Based Treatments via the NHS UK

The National Institute for Health and Care Excellence (NICE) Guidelines outline a structured, tiered management pathway for OA within the National Health Service (NHS) (NICE, 2022).

Care Pyramid Tier	Clinical Designation & Target	Key Treatment Interventions	Biological Mechanism & Clinical Context	Supporting Academic Evidence
Tier 1	CoreNon-Pharmacological (Mandatory) Target:All diagnosed individuals, regardless of radiological severity.	*Therapeutic Exercise: Supervised aerobic and resistance training (e.g., ESCAPE-pain pathway). * Weight Management: Structured 5% to 10% reduction for individuals with a BMI > 25.	*Formulates the mandatory baseline foundation of all long-term care plans. * Enhances synovial fluid circulation to provide cartilage nutrition. * Reverses quadriceps muscle atrophy to improve	NICE (2022); Fransen et al. (2015); Messier et al. (2013); Hurley et al. (2012)

		* Self-Management: Joint pacing and lifestyle alteration education.	mechanical joint stability. * Downregulates circulating, fat-derived pro-inflammatory adipokines (leptin, resistin).	
Tier 2	Pharmacological Adjuncts Target: Patients experiencing pain flare-ups that limit physical activity.	* Topical Agents: First-line topical NSAIDs (e.g., diclofenac 1% gel) for knees and hands. * Oral Agents: Systemic oral NSAIDs (e.g., ibuprofen, naproxen) always co-prescribed with a Proton Pump Inhibitor (PPI). * Localized Injections: Intra-articular corticosteroid injections.	* Employed strictly as a short-term adjunct to facilitate active rehabilitation, not as a standalone cure. * Provides targeted cyclooxygenase (COX) inhibition to reduce secondary synovitis and inflammatory prostaglandins. * Systemic oral options require a PPI (e.g., omeprazole) to safeguard the gastric mucosa against ulceration.	NICE (2022); Bannuru et al. (2019); Derry et al. (2016); Jüni et al. (2015)
Tier 3	Surgical Interventions	* Total Joint Reconstruction: Total Hip Arthroplasty (THA).	* Reserved as a final option when conservative non-pharmacological and pharmacological	NICE (2022); Carr et al. (2012); Price et al. (2018)

	Target: End-stage structural joint failure and severe refractory pain.	* Total Joint Replacement: Total Knee Arthroplasty (TKA).	measures are fully exhausted. * Physically removes eburnated subchondral bone and degraded articular cartilage, replacing them with prosthetic implants. * Eliminates severe mechanical bone-on-bone pain but carries invasive risks (e.g., deep vein thrombosis, prosthetic joint infection).	
--	---	---	---	--

Core Non-Pharmacological Interventions (Tier 1)

NICE guidelines emphasize that non-pharmacological interventions must form the baseline foundation of all care plans, regardless of radiological disease severity (NICE, 2022).

- Therapeutic Exercise:** Supervised aerobic and resistance training programs—such as the evidence-based **ESCAPE-pain** (Enabling Self-management and Coping with Arthritic Pain using Exercise) pathway—are widely integrated into NHS communities (Hurley et al., 2012). Regular, structured exercise promotes synovial fluid circulation, which helps deliver nutrients to the remaining articular cartilage. It also strengthens the surrounding muscles, improves joint stability, and downregulates systemic inflammatory markers (Fransen et al., 2015).
- Weight Management:** For individuals with a BMI exceeding 25, structured weight loss is recommended as a core treatment strategy (Christensen et al., 2007). Research demonstrates that losing 5% to 10% of total body weight significantly reduces mechanical load on weight-bearing joints and lowers circulating levels of destructive, fat-derived adipokines (Messier et al., 2013).

Pharmacological Management (Tier 2)

Pharmacotherapy is designated strictly as an short-term or long-term adjunct to facilitate active rehabilitation and exercise, rather than as a standalone cure (McAlindon et al., 2014).

1. **Topical Agents:** Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as diclofenac 1% gel, are recommended as first-line pharmacological options for knee and hand OA (NICE, 2022). These agents provide localized cyclooxygenase (COX) inhibition, reducing inflammatory prostaglandins in the joint tissues with minimal systemic absorption, which lowers the risk of systemic side effects (Derry et al., 2016).
2. **Oral NSAIDs:** If topical treatments do not provide sufficient relief, oral NSAIDs (such as ibuprofen or naproxen) may be considered (NICE, 2022). To protect the gastrointestinal tract, these must be co-prescribed with a Proton Pump Inhibitor (PPI), like omeprazole. This helps mitigate the risks of gastric mucosal damage, ulceration, and bleeding associated with systemic COX-1 and COX-2 inhibition (Bannuru et al., 2019).
3. **Intra-articular Injections:** Corticosteroid injections are typically reserved for patients experiencing acute, severe pain flare-ups associated with localized inflammation (Jüni et al., 2015). While they can provide significant short-term pain relief (generally lasting 4 to 12 weeks), they do not halt disease progression and are used primarily to open a "therapeutic window" that allows patients to engage in active physical therapy (Jüni et al., 2015).

Surgical Interventions (Tier 3)

Joint reconstruction, including Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA), is reserved for end-stage structural joint damage (Carr et al., 2012). Surgery is considered only when non-pharmacological and pharmacological treatments have been fully utilized, and the patient's pain, mobility, and overall quality of life remain severely compromised (NICE, 2022).

While joint replacement surgery is highly effective, offering 90% to 95% long-term pain reduction, it is an invasive procedure with inherent risks (Carr et al., 2012). Potential complications include deep vein thrombosis (DVT), prosthetic joint infection (PJI), and premature implant loosening, making careful patient assessment and selection essential (Price et al., 2018).

SECTION 3: Theoretical Perspectives, Models, and Policy Frameworks

3.1 Comparative Theoretical Models for Improved Outcomes

Managing chronic conditions like OA effectively requires moving away from reactive, acute care models toward proactive, preventative frameworks. Two key models illustrate this approach: the UK Chronic Care Model (specifically the House of Care framework) and the World Health Organization's (WHO) international Innovative Care for Chronic Conditions (ICCC) framework (Coulter et al., 2013; WHO, 2002).

Theoretical Framework	Model Component	Practical Translation to Osteoarthritis (OA) Management	System/Clinical Focus	Key Academic References
The UK House of Care	The Roof (System Org & Commissioning)	NHS Integrated Care Boards (ICBs) pooling budgets to commission community-led musculoskeletal (MSK) programs, such as ESCAPE-pain courses.	Localized organizational and administrative support.	Coulter et al. (2013); Adisa (2022)
	The Left Wall (The Empowered Patient)	Equipping the OA patient with self-management education, lifestyle alteration tools (diet, pacing), and home exercise layouts to build physical self-efficacy.	Patient-centered autonomy and activation.	Bodenheimer et al. (2002)
	The Right Wall (Prepared Professional)	Shifting GP/physiotherapist attitudes from paternalistic "prescribing" to open, collaborative goal-setting and shared decision-making.	Clinical attitude adjustment and partnership.	Wagner et al. (2001)
	The Floor (Personalised Care Planning)	The physical consultation where patient-specific goals (e.g., walking without a stick) are co-designed into a single, cohesive Care and Support Plan (PCSP).	Structured, co-produced patient encounter.	NICE (2021)
WHO Innovative Care for Chronic	Macro Level (National Policy & Leg)	National clinical strategies (like the Major Conditions Strategy) directing macro-level focus and resources toward non-	National-level policy, funding, and structural direction.	WHO (2002); DHSC (2023)

Conditions (ICCC)		communicable, degenerative joint disorders.		
	Meso Level (Organization & Community)	Integrating primary care networks with local municipal leisure services, parks, and third-sector charities (e.g., Versus Arthritis) to broaden rehabilitation options.	Community integration and resource sharing.	WHO (2002); HERE (2024)
	Micro Level (Coordinated Patient/MDT)	The direct, ongoing, collaborative interaction between the patient, their family, and the Multi-Disciplinary Team (MDT) to optimize joint health.	Localized relational care and direct support.	WHO (2002); Morden et al. (2015)

The UK Model: The House of Care Framework

The House of Care framework uses the structural components of a house to represent the essential elements of an integrated care delivery system (Coulter et al., 2013). For a patient living with OA, the model's key components must work together to support effective care:

- **The Left Wall (The Empowered Patient):** Focuses on equipping the patient with the knowledge, skills, and confidence to self-manage joint pain, set personal goals, and implement lifestyle changes (Bodenheimer et al., 2002).
- **The Right Wall (The Prepared Professional):** Moves away from a traditional, paternalistic prescribing model. Instead, clinicians act as partners in care, supporting self-management and collaborative decision-making (Wagner et al., 2001).
- **The Floor (Personalised Care Planning):** Represents the clinical encounter where the patient's personal goals and the clinician's medical expertise are integrated into a shared, co-produced care plan (NICE, 2021).
- **The Roof (System Organization and Commissioning):** Represents the administrative and funding infrastructure, such as NHS Integrated Care Boards (ICBs), that ensures resources are allocated to support community-based services (Adisa, 2022).

The International Model: WHO Innovative Care for Chronic Conditions (ICCC)

The ICCC framework expands on the patient-provider encounter by embedding it within broader organizational and political structures (WHO, 2002). Rather than focusing solely on the clinical consultation, the ICCC model emphasizes integration across three distinct tiers:

- **Micro Level (The Interaction Triad):** Promotes a collaborative partnership between the patient, their family, and the multi-disciplinary healthcare team (WHO, 2002).
- **Meso Level (Healthcare Organization and Community):** Integrates local community resources—such as municipal leisure centers, community gyms, and third-sector organizations—with primary care networks to expand support services (WHO, 2002).
- **Macro Level (Policy and Legislation):** Focuses on aligning national healthcare policies, funding structures, and public health mandates to support long-term, preventative care models (WHO, 2002).

Comparative Analysis

While both models advocate for proactive, patient-centered care, they differ in structural scope and application:

Evaluation Feature	UK House of Care Framework	WHO Innovative Care for Chronic Conditions (ICCC)
Primary Structural Focus	Concentrates on the clinical and operational interface within localized primary care settings (Coulter et al., 2013).	Focuses on a broad, macro-level systems integration spanning local, regional, and national levels (WHO, 2002).
Strengths in Application	Highly actionable within the NHS structure; helps improve primary care pathways and clinical efficiency (Adisa, 2022).	Provides a comprehensive framework for addressing the wider social and environmental determinants of health (WHO, 2002).
Inherent Limitations	May struggle to address wider, systemic socioeconomic inequalities that exist outside the healthcare clinic (Coulter et al., 2013).	Can be operationally complex and challenging to implement at the individual clinic or practice level (WHO, 2002).

3.2 Critical Examination of Political Health and Social Care Agendas

National and regional healthcare policies play a critical role in shaping how osteoarthritis care is structured and delivered across the NHS.

Political Health Agendas Comparison Table

Here is the structured evaluation table for the **Political Health Agendas** section, detailing how key UK policy frameworks shape, support, and challenge the delivery of community-based osteoarthritis (OA) care.

Policy Framework / Agenda	Core Strategic Elements	Implementation Mechanisms for OA Care	Key System Benefits	Operational Challenges & Risks
NHS Long Term Plan	* Focuses on moving care from secondary to primary/community settings. * Aims to reduce acute hospital pressure.	* Bypasses standard GP waiting lists. * Embeds specialized First Contact Practitioners (FCPs) directly within Primary Care Networks (PCNs) (NHS England, 2019).	* Provides patients with rapid, direct access to expert musculoskeletal (MSK) assessment. * Significantly reduces the baseline medical consultation load on general practitioners (NHS England, 2023).	* Significant regional workforce shortages in advanced practice physiotherapy. * Local funding variations result in unequal, post-code service distribution (GIRFT, 2026).
Major Conditions Strategy	* Targets six chronic conditions (including MSK) collectively. * Focuses on managing multi-morbidity and aging populations.	* Integrates digital health apps and home tracking (e.g., ESCAPE-pain digital tool). * Shifts focus to holistic, multi-morbid care plans (DHSC, 2023).	* Equips patients with portable, low-cost self-management tools. * Addresses concurrent conditions (e.g., OA pain alongside	* Severe risk of digital exclusion among older or socioeconomically deprived individuals. * Lack of technology access can widen existing health inequalities

			metabolic syndrome) (DHSC, 2023).	(Alexander et al., 2025).
Integrated Care Systems (ICSs)	* Promotes structural integration between health and social care services. * Emphasizes local geographic accountability.	* Unites NHS trusts, local municipal councils, and third-sector groups. * Supports pooled funding and joint community commissioning pathways (Adisa, 2022).	* Links clinical clinics directly to community leisure centers or hydrotherapy hubs. * Leverages charities (e.g., Versus Arthritis) for local support groups (HERE, 2024).	* Complex historical divisions in funding streams between health (NHS) and social care (Local Authorities). * Finding common operational ground across distinct organizational cultures is challenging (Adisa, 2022).

The NHS Long Term Plan

The NHS Long Term Plan emphasizes expanding community-based, integrated care to reduce pressure on secondary care and acute hospital services (NHS England, 2019). A key part of this strategy is funding **First Contact Practitioners (FCPs)**—highly specialized musculoskeletal (MSK) physiotherapists embedded directly within Primary Care Networks (PCNs) (NHS England, 2023).

By allowing patients with OA to bypass GP waiting lists and see an FCP directly, this pathway can accelerate access to non-pharmacological interventions like exercise programs and weight management services (GIRFT, 2026). However, shortages in the MSK workforce and variations in local funding mean that the availability and consistency of FCP services remain uneven across different regions of the UK (NHS England, 2023).

Major Conditions Strategy

The UK's Major Conditions Strategy targets six key clinical areas, including musculoskeletal conditions, in recognition of the challenges that multi-morbidity presents for an aging population (DHSC, 2023). The strategy emphasizes the use of digital health technologies, such as remote symptom-tracking apps, to support self-management and help patients manage joint pain and lifestyle changes at home (DHSC, 2023).

While digital tools can help expand service capacity, they also present a risk of widening health inequalities. Older adults, individuals with lower digital literacy, or those in socioeconomically disadvantaged areas may face digital exclusion due to a lack of access to devices or reliable internet connections, potentially limiting the reach of these initiatives (Alexander et al., 2025).

Integrated Care Systems (ICSs)

The Health and Care Act formalised the establishment of Integrated Care Systems (ICSs) across England, aiming to bring NHS services, local authorities, and third-sector organizations together to deliver more coordinated care (Adisa, 2022). In theory, an effective ICS can connect clinical primary care services directly with local community resources, such as council-run leisure centers, to offer subsidized exercise or hydrotherapy programs (HERE, 2024).

However, in practice, achieving true integration can be difficult. Historical funding divisions and separate operational budgets between healthcare (NHS) and social care (local authorities) often present administrative barriers to coordinated service delivery (Adisa, 2022).

SECTION 4: Recommendations for Person-Centred Care and Strategic Improvement

To address current gaps in care and improve long-term outcomes for individuals living with osteoarthritis, the following four strategic recommendations should be implemented across health and social care delivery systems:

1. Standardize Multi-Disciplinary Social Prescribing Pathways

NHS Integrated Care Boards should establish formal, non-clinical pathways that automatically connect primary care clinics with local community-based physical and social resources (Deeny et al., 2018).

- **Implementation:** Every patient diagnosed with moderate-to-severe OA should have access to a **Social Prescribing Link Worker**. This professional works with the patient to identify and connect them to local community-led physical activity programs (such as ESCAPE-pain), peer support networks, and subsidized hydrotherapy options.
- **Justification:** By connecting patients directly to community resources, this approach helps address the social isolation and physical deconditioning associated with chronic joint pain. It moves care out of clinical settings and into sustainable, local community environments, supporting long-term self-management (Alexander et al., 2025; Deeny et al., 2018).

2. Implement Universal Co-Produced Personalised Care and Support Plans (PCSPs)

Primary care networks should replace standard, transactional clinical reviews with collaborative, person-centered care planning conversations that actively involve the patient in managing their condition (NICE, 2021).

- **Implementation:** Clinical teams should utilize co-produced PCSPs that document patient-identified functional goals alongside standard clinical measures. Rather than focusing solely on

clinical pain scores, these plans should track self-selected goals, such as walking a specific distance or returning to a particular hobby.

- **Justification:** Aligning treatment plans with personal goals can enhance patient autonomy, build self-efficacy, and support better long-term adherence to recommended exercise and lifestyle changes (Bodenheimer et al., 2002; Deeny et al., 2018).

4. Expand Hybrid Digital Self-Management Support Programs

Recommendation Strategy	Target Audience / Setting	Key Implementation Mechanisms	Core Justification & Outcomes
1. Standardized Social Prescribing Pathways	Primary care settings / Moderate-to-severe OA cohorts	Dedicated Social Prescribing Link Workers. Direct referral pathways to community groups. Subsidized access to local exercise schemes (e.g., ESCAPE-pain).	Combates social isolation and chronic physical deconditioning. Decentralizes management from acute clinical settings to local community environments (Deeny et al., 2018).
2. Universal Co-Produced Personalised Care Plans	Primary Care Networks (PCNs) / Multi-morbid populations	Collaborative consultations replacing one-way clinical reviews. * Integration of patient-identified functional goals.	Maximizes patient autonomy and builds long-term self-efficacy. Aligning clinical care with personal aspirations increases

		* Mandated use of Personalised Care and Support Plans (PCSPs).	treatment adherence (Bodenheimer et al., 2002).
3. Hybrid Digital Self-Management Programs	Home-based care / Digitally capable individuals	* Implementation of the ESCAPE-pain digital app. * Blended tracking tools and instructional modules. * Telephone health coaching backstops for those at risk of digital exclusion.	* Facilitates continuous, accessible home rehabilitation. * Reduces pressure on baseline GP workloads while maintaining safe clinical oversight (GIRFT, 2026).
4. Multi-Morbid End-of-Life Pain Integration	Community nursing / Fragile, end-of-life individuals	* Advance Care Planning (ACP) integration. * Systematic screening for chronic musculoskeletal pain.	* Preserves patient dignity and comfort during advanced life stages. * Optimizes complex medication safety profiles in frail populations (DHSC, 2023).

		* Polypharmacy optimization to balance analgesic efficacy and drug interactions.	
--	--	--	--

Healthcare providers should adopt accessible, evidence-based digital tools to support ongoing home rehabilitation and education, while ensuring support is available for those who need it (NHS England, 2023).

- Implementation:** Commission and scale structured digital platforms, such as the **ESCAPE-pain digital app**, and pair them with telephone support from health coaches for patients who are less confident using technology. These platforms offer guided exercise videos, symptom-tracking tools, and educational modules on joint health.
- Justification:** Providing continuous, remote support helps patients manage their symptoms independently between clinical appointments. This can help reduce the need for routine primary care visits while maintaining clinical oversight and supporting patient safety (GIRFT, 2026; NHS England, 2023).

4. Embed Proactive Advance Care Planning into Multi-Morbid End-of-Life Frameworks

For older adults with advanced frailty or complex multi-morbidity, joint pain management should be integrated into palliative and end-of-life care pathways (DHSC, 2023).

- Implementation:** Train community nursing and palliative care teams to systematically assess and manage chronic musculoskeletal pain during advance care planning. Treatment plans must balance effective pain relief with the need to minimize cognitive side effects and drug interactions from complex medication regimens.
- Justification:** Managing severe, chronic pain in fragile individuals at the end of life protects patient dignity, reduces distress, and improves overall comfort and quality of life (DHSC, 2023; Morden et al., 2015).

References

- Adisa, O. (2022) Primary Care Network Leaders and the Health and Care Act: Navigating structural changes in the NHS. *Journal of Integrated Care*, 31(2), pp. 114-126.
- Alexander, J., Here, S. and Competence, M. (2025) The Acceptability of Musculoskeletal Community Appointment Days: A Mixed-Methods Service Evaluation. *Musculoskeletal Care*, 23(1), pp. e1235-e1244.

- Bannuru, R.R., Osani, M.C., Vaysbrot, E.E. et al. (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis and Cartilage*, 27(11), pp. 1578-1589.
- Bedson, J., Mottram, S., Thomas, E. and Peat, G. (2016) Knee pain and osteoarthritis in primary care: dynamic consequences for physical and mental health. *British Journal of General Practice*, 66(643), pp. e110-e117.
- Berenbaum, F., Eymard, F. and Houard, X. (2013) Osteoarthritis, inflammation and obesity: closer than you think. *Biomedicine & Pharmacotherapy*, 67(1), pp. 101-106.
- Bodenheimer, T., Lorig, K., Holman, H. and Grumbach, K. (2002) Patient self-management of chronic disease in primary care. *JAMA*, 288(19), pp. 2469-2475.
- Carey, T.S., Freburger, J.K., Holmes, G.M. et al. (2012) Care-seeking and outcomes for chronic low back pain and osteoarthritis in family networks. *Arthritis Care & Research*, 64(10), pp. 1558-1565.
- Carr, A.J., Robertsson, O., Graves, S. et al. (2012) Knee replacement. *The Lancet*, 379(9823), pp. 1331-1340.
- Christensen, R., Bartels, E.M., Astrup, A. and Bliddal, H. (2007) Effect of weight reduction in obese patients with knee osteoarthritis: a systematic review and meta-analysis. *Annals of the Rheumatic Diseases*, 66(4), pp. 433-439.
- Coulter, A., Roberts, S. and Dixon, A. (2013) Delivering better services for people with long-term conditions: Building the house of care. London: The King's Fund.
- Cross, M., Smith, E., Hoy, D. et al. (2014) The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. *Annals of the Rheumatic Diseases*, 73(7), pp. 1323-1330.
- Cui, A., Li, H., Wang, D. et al. (2020) Global, regional, and national burden of osteoarthritis, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Rheumatology International*, 40(3), pp. 359-373.
- Deeny, S., Steventon, A. and Alderwick, H. (2018) The impact of person-centred care on health outcomes and utilisation. London: The Health Foundation.
- Department of Health and Social Care (DHSC) (2023) Major conditions strategy: case for change and our strategic framework. London: Department of Health and Social Care.
- Derry, S., Conaghan, P., Da Silva, J.A. et al. (2016) Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database of Systematic Reviews*, (4), p. CD007400.
- Felson, D.T. (2013) Osteoarthritis as a disease of mechanics. *Osteoarthritis and Cartilage*, 21(1), pp. 10-15.

- Fransen, M., McConnell, S., Harmer, A.R. et al. (2015) Exercise for osteoarthritis of the knee: a Cochrane systematic review. *British Journal of Sports Medicine*, 49(24), pp. 1554-1557.
- Getting It Right First Time (GIRFT) (2026) Community MSK Delivery Programme and Referral Optimisation Operational Handbook. London: NHS England.
- Gignac, M.A., Backman, C.L., Davis, A.M. et al. (2011) Social role disruption and difficulty among adults with osteoarthritis. *Arthritis Care & Research*, 63(3), pp. 395-403.
- Hawker, G.A., Gignac, M.A., Badley, E. et al. (2011) A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. *Arthritis Care & Research*, 63(10), pp. 1382-1390.
- Health Engagement and Rehabilitation Excellence (HERE) (2024) Evaluating holistic community pathways for musculoskeletal care. Brighton: HERE Publications.
- Hunter, D.J. and Bierma-Zeinstra, S. (2019) Osteoarthritis. *The Lancet*, 393(10182), pp. 1745-1759.
- Hurley, M.V., Walsh, N.E., Mitchell, H.L. et al. (2012) Long-term outcomes and costs of an integrated rehabilitation program for chronic knee pain: A pragmatic, cluster randomized, controlled trial. *Arthritis Care & Research*, 64(2), pp. 238-247.
- Jüni, P., Hari, R., Rutjes, A.W. et al. (2015) Intra-articular corticosteroid for knee osteoarthritis. *Cochrane Database of Systematic Reviews*, (10), p. CD005328.
- Kapoor, M., Martel-Pelletier, J., Lajeunesse, D. et al. (2011) Role of pro-inflammatory cytokines in the pathophysiology of osteoarthritis. *Nature Reviews Rheumatology*, 7(1), pp. 33-42.
- King, L.K., March, L. and Anandacoomarasamy, A. (2013) Obesity & osteoarthritis. *Indian Journal of Medical Research*, 138(2), pp. 185-193.
- Kraus, V.B., Blanco, F.J., Englund, M. et al. (2015) Call for standardized definitions of osteoarthritis and risk factors. *Osteoarthritis and Cartilage*, 23(8), pp. 1233-1241.
- Loeser, R.F. (2010) Age-related changes in the musculoskeletal system and the development of osteoarthritis. *Clinics in Geriatric Medicine*, 26(3), pp. 371-386.
- Loeser, R.F., Goldring, S.R., Scanzello, C.R. and Goldring, M.B. (2012) Osteoarthritis: a disease of the joint as an organ. *Arthritis & Rheumatism*, 64(6), pp. 1697-1707.
- MacDonald, K.V., Sanmartin, C., Langlois, K. and Marshall, D.A. (2014) Symptom burden, financial strain, and quality of life in home nations osteoarthritis. *Health Reports*, 25(11), pp. 3-11.
- Mahjan, A., Tandon, V. and Verma, S. (2011) Osteoarthritis and menopause: the hormone link. *Journal of the International Menopause Society*, 14(4), pp. 201-207.

- Martel-Pelletier, J., Barr, A.J., Cicuttini, F.M. et al. (2016) Osteoarthritis. *Nature Reviews Disease Primers*, 2(1), pp. 1-18.
- McAlindon, T.E., Bannuru, R.R., Sullivan, M.C. et al. (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis and Cartilage*, 22(3), pp. 363-388.
- Messier, S.P., Mihalko, S.L., Legault, C. et al. (2013) Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes in overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *JAMA*, 310(12), pp. 1263-1273.
- Morden, A., Jinks, C. and Ong, B.N. (2015) Lay perspectives on chronic joint pain management within family systems. *Qualitative Health Research*, 25(2), pp. 190-201.
- National Institute for Health and Care Excellence (NICE) (2021) Shared decision making (NICE Guideline NG197). London: NICE.
- National Institute for Health and Care Excellence (NICE) (2022) Osteoarthritis in adults: diagnosis and management (NICE Guideline NG226). London: NICE. Available at: <https://www.nice.org.uk/guidance/ng226> (Accessed: 24 June 2026).
- NHS England (2019) The NHS Long Term Plan. London: NHS England.
- NHS England (2023) An improvement framework to reduce community musculoskeletal waits while delivering best outcomes and experiences. London: NHS England.
- Neogi, T. (2013) The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis and Cartilage*, 21(9), pp. 1145-1153.
- Øiestad, B.E., Engebretsen, L., Storheim, K. and Risberg, M.A. (2010) Knee osteoarthritis after anterior cruciate ligament injury: a systematic review. *American Journal of Sports Medicine*, 38(11), pp. 2346-2354.
- Price, A.J., Alvand, A., Troelsen, A. et al. (2018) Knee replacement. *The Lancet*, 392(10158), pp. 1672-1682.
- Sharma, A., Keng, M. and Peat, G. (2016) Anxiety and depression burden in painful musculoskeletal conditions: an epidemiological review. *Rheumatology*, 55(4), pp. 612-621.
- Steinmetz, J.D., Bourne, R.R., Briant, P.S. et al. (2023) Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology*, 5(9), pp. e508-e522.
- Stubbs, B., Almirall, J., Nicklett, E. and Vancampfort, D. (2016) The deconditioning cascade in osteoarthritis: a meta-analysis of cardiovascular and metabolic comorbidities. *Osteoarthritis and Cartilage*, 24(7), pp. 1150-1159.

- Thomas, E., Peat, G. and Croft, P. (2014) Defining and mapping the trajectory of joint pain in large populations. *Rheumatology*, 53(3), pp. 443-452.
- Versus Arthritis (2022) *The State of Musculoskeletal Health 2022: Arthritis and other musculoskeletal conditions in the UK*. Chesterfield: Versus Arthritis.
- Versus Arthritis (2024) *The State of Musculoskeletal Health 2024*. Chesterfield: Versus Arthritis.
- Wagner, E.H., Austin, B.T., Davis, C. et al. (2001) Improving outcomes in chronic illness. *Managed Care Quarterly*, 9(4), pp. 14-32.
- Wilkie, R., Pradhan, S. and Jordan, K.P. (2014) Socioeconomic deprivation and restricted social participation in adults with hip and knee osteoarthritis. *Arthritis Care & Research*, 66(11), pp. 1665-1672.
- World Health Organization (WHO) (2002) *Innovative Care for Chronic Conditions: Building Blocks for Action*. Geneva: World Health Organization.